SKOG102 (10-20 mg/kg; i.p.) inhibits GBM4 tumor growth in mice[1].
SKOG102 (5 mg/kg; i.p.) accumulates in the tumor even over a relatively brief time period and the plasma and brain concentrations are almost identical at 4 hours after injection in mice[1].
| Animal Model: | NSG mice were inoculated in each flank with GBM4 cells[1] |
| Dosage: | 10, 15, and 20 mg/kg; dissolved in solutol:PEG400:water (20%:40%:40%) |
| Administration: | Intraperitoneal injection; first 2 weeks (from day 33 to 46) 10 mg/kg, third week (from day 47 to 54) 15 mg/kg, fourth week (from 55 to 66) first 3 days 20 mg/kg, 2 days break, then alternate days from day 60 to 66 |
| Result: | Significantly attenuated tumor growth.
|
![1-(3,4-dichlorophenyl)-2-[4-[(1-ethyl-3-piperidyl)amino]-6-methyl-pyrimidin-2-yl]guanidine Structure](/CAS/GIF/21062-28-2.gif)
